Shareholder Class Action

     Pfizer, as successor to Wyeth Pharmaceuticals, inflated share price by false and misleading statements about an Alzheimer’s drug, B-Mab, and the share price dropped by 12 percent in a day when the truth came out, shareholders claim in Newark Federal Court.

%d bloggers like this: